ClinicalTrials.gg
CompletedNCT02151994Updated Jan 5, 2016Results posted

Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.

A Phase 1 interventional study of BIA 5-1058 and Placebo in Hypertension and Chronic Heart Failure, sponsored by Bial - Portela C S.A.. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-05.

Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 152 studies in Hypertension with a site in Netherlands — 23 open to participants now, 32 under way, 7 of them phase 3. Hypertension · Netherlands.

Enrollment
70th of 127
124 · median 139
Started
2011
with 8 others
Phase 1
2 of 152
none open now
Registered
83rd of 152
by date

Among the 152 studies in Hypertension with a site in Netherlands, this one is the 70th largest by enrollment of the 127 interventional ones that give a count, is one of 9 that started in 2011, is one of 2 in phase 1, and was the 83rd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

23 of the 152 studies in Hypertension with a site in Netherlands are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Hypertension with a site in Netherlands, or all of them as a file.
02

Study summary

The purpose of this study is to to assess the safety and tolerability of BIA 5 1058 after single and multiple oral doses

Read the detailed description

This was a Phase 1, double blind, randomised, placebo-controlled combined single ascending dose (SAD), including food interaction (food effect, FE) analysis, and multiple ascending dose (MAD) study.

SAD: This part consisted of an eligibility screening period, one study period involving administration of single doses of BIA 5-1058 or placebo according to a randomized design, and a follow-up period. Nine sequential groups of 8 healthy young male subjects were dosed. Within each group, 6 subjects were randomised to receive BIA 5-1058 and 2 subjects were randomised to receive placebo. In this first-in-human study, the subjects participating at the lowest dose level of 5 mg were dosed according to a sentinel dosing design to ensure optimal safety. Initially, 2 subjects were dosed; 1 subject with BIA 5-1058 and 1 subject with placebo. After the safety and tolerability results of the first 24 h following dosing for the initial subjects had been found to be acceptable to the MI, the other 6 subjects of the lowest dose level were dosed.

MAD: This part consisted of an eligibility screening period, one study period involving administration of multiple doses of BIA 5-1058 or placebo once daily for 10 days, and a follow-up period. Five sequential groups of 8 healthy young male subjects were dosed.

Within each group, 6 subjects were randomised to receive BIA 5-1058 and 2 subjects were randomised to receive placebo.

The starting dose of 50 mg was chosen taking into consideration the dose range of the previous SAD sequential groups and was approved by the IEC. Escalation to the next higher dose and the determination of the next dose level was based on safety, tolerability and available PK results of the previously administered dose

FE: This part consisted of an eligibility screening period, an open-label two-way crossover study period, and a follow-up period. One group of 12 subjects received single doses of 400 mg BIA 5-1058 during 2 treatment periods, once after having fasted overnight and once after consumption of a high fat breakfast. Each treatment was separated by a period of at least 7 days. The treatment sequence was determined by randomisation.

03

Conditions studied

  • Hypertension and Chronic Heart Failure

Keywords

  • BIA 5-1058
  • hypertension
  • chronic heart failure
  • cardiovascular disorders
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects were eligible for the study if they met all the following inclusion criteria:

  • Gender - male
  • Age - 18 - 55 years, inclusive
  • (BMI) - 18.0 - 30.0 kg m2 (BMI (kg m2) = Body weight (kg) - Heigh t2 (m 2))
  • Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, power drinks), grapefruit (juice) and tobacco products from 48 h prior to entry in the clinical research centre until discharge
  • Medical history without major pathology
  • Normal resting supine blood pressure and pulse rate showing no deviations as judged by the MI
  • Computerised (12-lead) recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the MI
  • All values for haematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the MI
  • Willingness to sign the written ICF

Exclusion criteria

Exclusion Criteria:

Subjects were excluded from participation if any of the following exclusion criteria applied

  • Any significant cardiovascular (e.g. hypertension), hepatic, renal, respiratory (e.g. childhood asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia), immunologic, haematological, neurologic, or psychiatric disease
  • An automatic reading at screening or enrolment of + 440 ms.
  • Evidence of pathology
  • Mental handicap
  • History of relevant drug and or food allergies
  • Smoking more than 10 cigarettes and or cigars and or pipes daily
  • History of alcohol abuse or drug addiction (including soft drugs like cannabis products)
  • Use of any prescription drug within 30 days before study drug administration with the exception of influenza vaccination
  • Use of any over-the-counter drugs including health supplements, herbal supplements such as St. John's Wort extract (except for the occasional use of acetaminophen (paracetamol), aspirin and vitamins - 100 recommended daily allowance) within 7 days before study drug administration. The use of paracetamol and or topical medication was allowed up to 3 days before entrance into the clinical research facility
  • Participation in a drug study within 90 days prior to drug administration
  • Participation in more than 3 other drug studies in the 10 months preceding the start of this study (this was the first administration of study drug)
  • Donation of more than 50 mL of blood within 90 days prior to first drug administration
  • Donation of more than 1.5 litres of blood in the 10 months preceding the start of this study (this was the first administration of study drug)
  • Positive screen on drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids), barbiturates, benzodiazepines, tricyclic antidepressants and alcohol
  • Intake of more than 24 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
  • Positive screen on surface antigen (HBsAg)
  • Positive screen on anti virus (HCV)
  • Positive screen on anti (HIV) 1 - 2
  • Acute disease state indicated as clinically relevant by the MI (e.g. nausea, vomiting, fever, diarrhoea) within 7 days before the first drug administration
  • Non-willingness to consume the Food and Drug Administration (FDA) breakfast (FE part only)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    BIA 5-1058

    BIA 5-1058 (5, 25 and 100 mg) tablets

    Drug: BIA 5-1058

  • Placebo comparator
    Placebo

    tablets, visually matching active medication

    Drug: Placebo

Interventions

  • oral administration

    Also known as: Zamicastat

  • DrugPlacebo

    oral administration

06

What researchers measure

Primary outcomes

  1. Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Single Ascending Dose (SAD) Period

    Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".

    Time frame: Just before drug administration and twice daily until 72 h after (last) drug administration

  2. Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Multiple Ascending Dose (MAD) Period

    Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".

    Time frame: Just before drug administration and twice daily until 72 h after (last) drug administration

  3. Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Food Effect (FE)

    Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".

    Time frame: Just before drug administration and twice daily until 72 h after (last) drug administration

07

Results

Posted Jan 5, 2016

Participant flow

Study period : Date of first screening to last follow-up: 03 March 2011 - 13 January 2012;

Single Ascending Dose (SAD)
Participant flow — Single Ascending Dose (SAD)
MilestonePlacebo5 mg25 mg50 mg100 mg200 mg400 mg800 mg1200 mg1600 mg2400 mg400 mg Fasted400 mg Fed
Started18666666606600
Completed18666666606600
Not completed0000000000000
Multiple Ascending Dose (MAD)
Participant flow — Multiple Ascending Dose (MAD)
MilestonePlacebo5 mg25 mg50 mg100 mg200 mg400 mg800 mg1200 mg1600 mg2400 mg400 mg Fasted400 mg Fed
Started10006666060000
Completed10006666060000
Not completed0000000000000
Food Effect (FE): Fasted
Participant flow — Food Effect (FE): Fasted
MilestonePlacebo5 mg25 mg50 mg100 mg200 mg400 mg800 mg1200 mg1600 mg2400 mg400 mg Fasted400 mg Fed
Started00000000000120
Completed00000000000120
Not completed0000000000000
Food Effect (FE): Fed
Participant flow — Food Effect (FE): Fed
MilestonePlacebo5 mg25 mg50 mg100 mg200 mg400 mg800 mg1200 mg1600 mg2400 mg400 mg Fasted400 mg Fed
Started00000000000012
Completed00000000000012
Not completed0000000000000

Outcome measures

PrimaryPercentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Single Ascending Dose (SAD) Period

Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".

Time frame:
Just before drug administration and twice daily until 72 h after (last) drug administration
Reported as:
Number · % of subject with TEAEs related to SM
Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Single Ascending Dose (SAD) Period
% of subject with TEAEs related to SMPlacebo5 mg25 mg50 mg100 mg200 mg400 mg800 mg1600 mg2400 mg
Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Single Ascending Dose (SAD) Period28000001717067
PrimaryPercentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Multiple Ascending Dose (MAD) Period

Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".

Time frame:
Just before drug administration and twice daily until 72 h after (last) drug administration
Reported as:
Number · % of subject with TEAEs related to SM
Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Multiple Ascending Dose (MAD) Period
% of subject with TEAEs related to SMPlacebo50 mg100 mg200 mg400 mg1200 mg
Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Multiple Ascending Dose (MAD) Period3005033033
PrimaryPercentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Food Effect (FE)

Just before drug administration and twice daily until 72 h after (last) drug administration, subjects were asked non-leading questions to determine the occurrence of AEs. Subjects were asked in general terms about any AEs at regular intervals during each study period. In addition, all AEs reported spontaneously during the course of the study were recorded. All answers were assessed by the Medical Investigator (MI), coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 14.0) and recorded in the AEs Record. The intensity of the AEs was rated as "mild", "moderate" or "severe" and the relationship between the AEs and the study medication was indicated as "not related", "unlikely", "possible", "probable" or ''definite".

Time frame:
Just before drug administration and twice daily until 72 h after (last) drug administration
Reported as:
Number · % of subject with TEAEs related to SM
Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Food Effect (FE)
% of subject with TEAEs related to SM400 mg Fasted400 mg Fed
Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Food Effect (FE)017

Adverse events

Collected over Just before drug administration and twice daily until 72 h after (last) drug administration. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (SAD)—0/18 (0%)11/18 (61.1%)
5 mg (SAD)—0/6 (0%)0/6 (0%)
25 mg (SAD)—0/6 (0%)2/6 (33.3%)
50 mg (SAD)—0/6 (0%)3/6 (50%)
100 mg (SAD)—0/6 (0%)2/6 (33.3%)
200 mg (SAD)—0/6 (0%)4/6 (66.7%)
400 mg (SAD)—0/6 (0%)4/6 (66.7%)
800 mg (SAD)—0/6 (0%)3/6 (50%)
1600 mg (SAD)—0/6 (0%)1/6 (16.7%)
2400 mg (SAD)—0/6 (0%)4/6 (66.7%)
400 mg Fasted (FE Period)—0/12 (0%)3/12 (25%)
400 mg Fed (FE Period)—0/12 (0%)5/12 (41.7%)
Placebo (MAD Period)—0/10 (0%)8/10 (80%)
50 mg (MAD Period)—0/6 (0%)5/6 (83.3%)
100 mg (MAD Period)—0/6 (0%)3/6 (50%)
200 mg (MAD Period)—0/6 (0%)5/6 (83.3%)
400 mg (MAD Period)—0/6 (0%)3/6 (50%)
1200 mg (MAD Period)—0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 62
Most frequent other events
EventPlacebo (SAD)5 mg (SAD)25 mg (SAD)50 mg (SAD)100 mg (SAD)200 mg (SAD)400 mg (SAD)800 mg (SAD)1600 mg (SAD)2400 mg (SAD)400 mg Fasted (FE Period)400 mg Fed (FE Period)Placebo (MAD Period)50 mg (MAD Period)100 mg (MAD Period)200 mg (MAD Period)400 mg (MAD Period)1200 mg (MAD Period)
headacheNervous system disorders4/180/60/60/60/60/61/61/60/63/60/120/123/102/60/61/60/65/6
fatigueGeneral disorders0/180/61/60/60/61/60/60/60/60/60/120/121/100/62/64/60/60/6
nauseaGastrointestinal disorders0/180/60/61/60/60/60/60/60/62/60/120/120/102/60/60/60/63/6
abdominal painGastrointestinal disorders0/180/60/60/60/60/60/60/60/60/60/121/121/101/60/60/60/63/6
diarrhoeaGastrointestinal disorders0/180/60/62/60/60/61/61/61/60/60/121/120/101/60/60/60/60/6
application site irritationGeneral disorders1/180/60/60/60/60/60/60/60/60/60/120/120/100/60/62/60/61/6
dizzinessNervous system disorders1/180/60/60/61/60/60/61/60/62/60/120/121/100/60/61/60/61/6
dizziness posturalNervous system disorders0/180/60/60/62/60/60/60/60/60/60/120/121/100/60/60/60/60/6
catheter site related inflammationGeneral disorders0/180/60/60/60/60/60/60/60/60/60/120/120/100/60/62/60/61/6
catheter site related reactionGeneral disorders2/180/60/60/61/60/60/60/60/60/61/121/122/100/60/60/60/60/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Single Ascending Dose (SAD)Multiple Ascending Dose (MAD)Food Interaction (Food Effect, FE) AnalysisTotal
<=18 years0202
Between 18 and 65 years723812122
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Single Ascending Dose (SAD)Multiple Ascending Dose (MAD)Food Interaction (Food Effect, FE) AnalysisTotal
Female0000
Male724012124
08

Study locations

1 site
  • PRA
    Zuidlaren, 9471 GP, Netherlands
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2014
First posted
Jun 2, 2014
Start
Mar 2011
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Jan 5, 2016
Last update
Jan 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02151994
Responsible party
Sponsor
First posted
Jun 2, 2014
Start date
Mar 2011
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Jan 5, 2016
Last update
Jan 5, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zamicastat

Start the discussion